Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents

Bone-modifying agents (BMAs), with bone-resorptive inhibitory effects, such as zoledronic acid and denosumab, are widely used at higher doses for bone-related events caused by bone metastasis of malignant tumors. These drugs have been suggested to be associated with atypical femoral fractures (AFFs)...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Tomoaki Fukui, Keisuke Oe, Teruya Kawamoto, Masayuki Morishita, Ikuo Fujita, Shunsuke Takahara, Atsushi Sakurai, Takashi Iwakura, Keiji Yoshida, Kenjiro Ito, Etsuo Shoda, Takafumi Hiranaka, Masaya Tsunoda, Ryosuke Kuroda, Takahiro Niikura
Format:	Artigo
Język:	Inglês
Wydane:	Elsevier 2023-06-01
Seria:	Journal of Bone Oncology
Hasła przedmiotowe:	Atypical femoral fracture Bone metastasis Zoledronic acid Denosumab Bone-modifying agent Bisphosphonate
Dostęp online:	http://www.sciencedirect.com/science/article/pii/S2212137423000118
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!